Literature DB >> 34967914

Improved myocardial blood flow estimation with residual activity correction and motion correction in 18F-flurpiridaz PET myocardial perfusion imaging.

Yuka Otaki1, Serge D Van Kriekinge1, Chih-Chun Wei1, Paul Kavanagh1, Ananya Singh1, Tejas Parekh1, Marcelo Di Carli2, Jamshid Maddahi3, Arkadiusz Sitek4, Christopher Buckley5, Daniel S Berman1, Piotr J Slomka6.   

Abstract

PURPOSE: We sought to evaluate the diagnostic performance for coronary artery disease (CAD) of myocardial blood flow (MBF) quantification with 18F-flurpiridaz PET using motion correction (MC) and residual activity correction (RAC).
METHODS: In total, 231 patients undergoing same-day pharmacologic rest and stress 18F-flurpiridaz PET from Phase III Flurpiridaz trial (NCT01347710) were studied. Frame-by-frame MC was performed and RAC was accomplished by subtracting the rest residual counts from the dynamic stress polar maps. MBF and myocardial flow reserve (MFR) were derived with a two-compartment early kinetic model for the entire left ventricle (global), each coronary territory, and 17-segment. Global and minimal values of three territorial (minimal vessel) and segmental estimation (minimal segment) of stress MBF and MFR were evaluated in the prediction of CAD. MBF and MFR were evaluated with and without MC and RAC (1: no MC/no RAC, 2: no MC/RAC, 3: MC/RAC).
RESULTS: The area-under the receiver operating characteristics curve (AUC [95% confidence interval]) of stress MBF with MC/RAC was higher for minimal segment (0.89 [0.85-0.94]) than for minimal vessel (0.86 [0.81-0.92], p = 0.03) or global estimation (0.81 [0.75-0.87], p < 0.0001). The AUC of MFR with MC/RAC was higher for minimal segment (0.87 [0.81-0.93]) than for minimal vessel (0.83 [0.76-0.90], p = 0.014) or global estimation (0.77 [0.69-0.84], p < 0.0001). The AUCs of minimal segment stress MBF and MFR with MC/RAC were higher compared to those with no MC/RAC (p < 0.001 for both) or no MC/no RAC (p < 0.0001 for both).
CONCLUSIONS: Minimal segment MBF or MFR estimation with MC and RAC improves the diagnostic performance for obstructive CAD compared to global assessment.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  18F-Flurpiridaz PET; Motion correction; Myocardial blood flow; Myocardial flow reserve; Residual activity correction

Mesh:

Year:  2021        PMID: 34967914     DOI: 10.1007/s00259-021-05643-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  29 in total

1.  Diagnostic value of 13N-ammonia myocardial perfusion PET: added value of myocardial flow reserve.

Authors:  Michael Fiechter; Jelena R Ghadri; Cathérine Gebhard; Tobias A Fuchs; Aju P Pazhenkottil; Rene N Nkoulou; Bernhard A Herzog; Christophe A Wyss; Oliver Gaemperli; Philipp A Kaufmann
Journal:  J Nucl Med       Date:  2012-06-29       Impact factor: 10.057

2.  Improved cardiac risk assessment with noninvasive measures of coronary flow reserve.

Authors:  Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Mariya Gaber; Gilda Di Carli; Ron Blankstein; Sharmila Dorbala; Arkadiusz Sitek; Michael J Pencina; Marcelo F Di Carli
Journal:  Circulation       Date:  2011-10-17       Impact factor: 29.690

3.  Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography.

Authors:  Masanao Naya; Venkatesh L Murthy; Viviany R Taqueti; Courtney R Foster; Josh Klein; Mariya Garber; Sharmila Dorbala; Jon Hainer; Ron Blankstein; Frederick Resnic; Marcelo F Di Carli
Journal:  J Nucl Med       Date:  2014-01-09       Impact factor: 10.057

4.  Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.

Authors:  Jamshid Maddahi; Johannes Czernin; Joel Lazewatsky; Sung-Cheng Huang; Magnus Dahlbom; Heinrich Schelbert; Richard Sparks; Alexander Ehlgen; Paul Crane; Qi Zhu; Marybeth Devine; Michael Phelps
Journal:  J Nucl Med       Date:  2011-08-17       Impact factor: 10.057

5.  Absolute flow or myocardial flow reserve for the detection of significant coronary artery disease?

Authors:  Esa Joutsiniemi; Antti Saraste; Mikko Pietilä; Maija Mäki; Sami Kajander; Heikki Ukkonen; Juhani Airaksinen; Juhani Knuuti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-01-09       Impact factor: 6.875

6.  Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.

Authors:  Jamshid Maddahi; Joel Lazewatsky; James E Udelson; Daniel S Berman; Rob S B Beanlands; Gary V Heller; Timothy M Bateman; Juhani Knuuti; Cesare Orlandi
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

7.  Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease?

Authors:  Maria C Ziadi; Robert A Dekemp; Kathryn Williams; Ann Guo; Jennifer M Renaud; Benjamin J W Chow; Ran Klein; Terrence D Ruddy; May Aung; Linda Garrard; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2012-03-14       Impact factor: 5.952

8.  Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.

Authors:  Jamshid Maddahi; Frank Bengel; Johannes Czernin; Paul Crane; Magnus Dahlbom; Heinrich Schelbert; Richard Sparks; Michael Phelps; Joel Lazewatsky
Journal:  J Nucl Cardiol       Date:  2018-11-28       Impact factor: 5.952

9.  Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

Authors:  Daniel S Berman; Jamshid Maddahi; B K Tamarappoo; Johannes Czernin; Raymond Taillefer; James E Udelson; C Michael Gibson; Marybeth Devine; Joel Lazewatsky; Gajanan Bhat; Dana Washburn
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

10.  Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.

Authors:  René R S Packard; Sung-Cheng Huang; Magnus Dahlbom; Johannes Czernin; Jamshid Maddahi
Journal:  J Nucl Med       Date:  2014-07-28       Impact factor: 10.057

View more
  3 in total

1.  Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC.

Authors:  Xin Zhou; Shuailiang Wang; Xiaoxia Xu; Xiangxi Meng; Huiyuan Zhang; Annan Zhang; Yufei Song; Hua Zhu; Zhi Yang; Nan Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-11       Impact factor: 10.057

2.  Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology.

Authors:  Xiaohui Chen; Xinran Liu; Lijuan Wang; Wenlan Zhou; Yin Zhang; Ying Tian; Jianer Tan; Ye Dong; Lilan Fu; Hubing Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-07       Impact factor: 10.057

3.  [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers.

Authors:  Yuchun Wei; Jinsong Zheng; Li Ma; Xiaoli Liu; Shengnan Xu; Shijie Wang; Jinli Pei; Kai Cheng; Shuanghu Yuan; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-09       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.